Investor Presentaiton

Investor presentation ADA 2019 The FOCUS trial will evaluate long-term effects of semaglutide vs placebo regarding diabetic retinopathy Poor glucose control causes damage to blood vessels which can lead to diabetic retinopathy Healthy eye Diabetic eye FOCUS trial design Superior Rectus Muscle Sclera Lens Pupil Cornea Ciliary body Inferior Rectus Muscle Retina Fovea Optic Disc Optic nerve Central Retinal Vein and Artery Abnormal Blood Vessels Aneurysm Hemorrhages "Cotton Wool" Spots Slide 10 Randomised: ~1,500 patients with type 2 diabetes Antidiabetic SOC + semaglutide 0.5-1.0 mg sc QW Antidiabetic SOC+ placebo 5 years 1 in 3 people living with type 2 diabetes have some degree of diabetic retinopathy¹ About 5-10% of people living with diabetes will develop a vision threatening form of the disease² The global market for treating diabetic retinopathy is currently estimated to be around USD 6 billion³ Trial objective To assess the long-term effects of semaglutide compared with placebo, both added to standard of care, with respect to diabetic retinopathy development and progression Inclusion criteria . Diabetes duration >10 years • HbA1c 7-10% • Exclusion: unstable or active eye disease Trial initiation: Q2 2019 1 IDF Atlas, Eighth edition 2017, 2 Tien Y. Wong, Chui Ming Gemmy Cheung, Michael Larsen, Sanjay Sharma and Rafael Simó, Diabetic retinopathy, Nature Reviews, Disease Primers, VOLUME 2, 2016, 3 Grand View Research; Diabetic Retinopathy Market Analysis Report By Type, published February 2018 QW: once-weekly; sc: subcutaneous; SOC: standard of care novo nordisk

View entire presentation